Global Blood Therapeutics (GBT) Price Target Increased to $70.00 by Analysts at Needham & Company LLC
Global Blood Therapeutics (NASDAQ:GBT) had its price objective increased by equities research analysts at Needham & Company LLC from $51.00 to $70.00 in a report issued on Thursday. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price objective points to a potential upside of 82.53% from the stock’s previous close.
GBT has been the subject of a number of other reports. Oppenheimer set a $53.00 price objective on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research note on Monday, October 30th. Cantor Fitzgerald set a $61.00 price objective on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research note on Monday. J P Morgan Chase & Co reiterated a “buy” rating on shares of Global Blood Therapeutics in a report on Monday, October 23rd. BidaskClub downgraded Global Blood Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, September 14th. Finally, Zacks Investment Research upgraded Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a report on Tuesday, October 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $62.07.
Shares of Global Blood Therapeutics (NASDAQ:GBT) opened at $38.35 on Thursday. Global Blood Therapeutics has a 52 week low of $13.35 and a 52 week high of $45.85.
Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings data on Thursday, November 2nd. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.04). During the same quarter in the prior year, the firm earned ($0.58) EPS. research analysts forecast that Global Blood Therapeutics will post -2.55 earnings per share for the current year.
In related news, VP Peter Radovich sold 12,500 shares of the stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $35.00, for a total value of $437,500.00. Following the transaction, the vice president now owns 2,684 shares in the company, valued at $93,940. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Charles J. Homcy sold 70,000 shares of the stock in a transaction that occurred on Friday, October 27th. The stock was sold at an average price of $33.97, for a total value of $2,377,900.00. Following the completion of the transaction, the director now owns 83,328 shares in the company, valued at approximately $2,830,652.16. The disclosure for this sale can be found here. Insiders sold 88,500 shares of company stock worth $3,003,350 in the last 90 days. 5.30% of the stock is currently owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in the stock. State Street Corp grew its holdings in Global Blood Therapeutics by 217.9% during the second quarter. State Street Corp now owns 2,138,323 shares of the company’s stock valued at $58,479,000 after purchasing an additional 1,465,595 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in Global Blood Therapeutics by 189.5% during the third quarter. Point72 Asset Management L.P. now owns 2,022,700 shares of the company’s stock valued at $62,805,000 after purchasing an additional 1,323,934 shares during the last quarter. Janus Henderson Group PLC acquired a new position in Global Blood Therapeutics during the second quarter valued at approximately $26,919,000. BlackRock Inc. grew its holdings in Global Blood Therapeutics by 30.0% during the second quarter. BlackRock Inc. now owns 3,404,538 shares of the company’s stock valued at $93,114,000 after purchasing an additional 785,691 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in Global Blood Therapeutics by 15.7% during the second quarter. Vanguard Group Inc. now owns 2,933,251 shares of the company’s stock valued at $80,224,000 after purchasing an additional 397,271 shares during the last quarter. Hedge funds and other institutional investors own 90.48% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Global Blood Therapeutics (GBT) Price Target Increased to $70.00 by Analysts at Needham & Company LLC” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/12/14/global-blood-therapeutics-gbt-price-target-increased-to-70-00-by-analysts-at-needham-company-llc.html.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.